Related Experiment Video
Updated: Mar 24, 2026
07:34
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
3.3K
An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?
S Burman1, E C Hoedt, S Pottenger
1The University of Queensland Diamantina Institute, and Faculty of Medicine and Biomedical Sciences, Translational Research Institute, University of Queensland, St. Lucia, Brisbane, Australia.
Digestive Diseases (Basel, Switzerland)
|March 17, 2016
Summary
Gut microbiota changes, or dysbiosis, are linked to inflammatory bowel disease (IBD). Understanding these microbial shifts and their ecological fitness is key to developing new IBD treatments.
Area of Science:
- Microbiology
- Gastroenterology
- Immunology
Background:
- Inflammatory bowel disease (IBD) is influenced by gut microbiota, but specific causative pathogens remain elusive.
- Culture-independent techniques like metagenomics offer new insights into IBD's microbial landscape.
- Dysbiosis, or altered gut bacterial profiles, is consistently observed in IBD patients.
Purpose of the Study:
- To explore the role of gut microbiota in the onset, remission, and recurrence of IBD.
- To identify specific microbial taxa contributing to or protecting against IBD.
- To understand the ecological factors influencing microbial communities in IBD.
Main Methods:
- Utilized metagenomics and culture-independent techniques for microbial community analysis.
- Analyzed observational, case-control, and longitudinal studies of IBD patients.
- Investigated both numerically predominant and lesser-abundant microbial taxa, including archaea.
Main Results:
- Confirmed significant gut bacterial profile changes (dysbiosis) in IBD patients.
- Identified 'colitogenic' bacteria and alterations in immunogenic methanogenic archaea.
- Longitudinal studies suggest 'anti-inflammatory' microbiota may promote remission in Crohn's disease.
Conclusions:
- Gut microbiota composition and function are critical in IBD pathogenesis.
- Specific microbes exert pro- or anti-inflammatory effects, influencing IBD onset and recurrence.
- Further research into microbial ecological fitness is needed for novel IBD therapeutic strategies.
More Related Videos
Related Concept Videos
01:18Functions of the Gut Microbiota
5
The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...
5
01:29Inflammatory Bowel Disease IV: Pharmacological Management
912
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
912
01:17Irritable Bowel Syndrome I: Introduction
1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
01:27Microbiota of the Large Intestine
3
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
3
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
725
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725